<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00362947</url>
  </required_header>
  <id_info>
    <org_study_id>The Steflux study</org_study_id>
    <nct_id>NCT00362947</nct_id>
  </id_info>
  <brief_title>Different Doses and Duration of Low Molecular Weight Heparin (Parnaparin)in Superficial Vein Thrombosis</brief_title>
  <official_title>Randomized Clinical Study of Different Treatment Doses and Duration of Low Molecular Weight Heparin (Parnaparin) in Superficial Vein Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal treatment of superficial venous thrombosis (SVT) is still uncertain. Though low&#xD;
      molecular weight heparin (LMWH) is considered the treatment of choice, studies conducted so&#xD;
      far do not give clear indications of the optimal dose and duration of treatment. This study&#xD;
      aims to evaluate whether an intermediate therapeutic dose of LMWH (parnaparin) is more&#xD;
      effective than a prophylactic dose and also to assess whether 10 rather than 30 days are&#xD;
      sufficient for treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outpatients with an episode of SVT of the grand saphenous vein (for at least 4 cm), and/or&#xD;
      SVT of the small saphenous vein (for at least 4 cm), and/or SVT of a collateral vein of the&#xD;
      large saphenous vein of the thigh (for at least 4cm) are included in this prospective,&#xD;
      randomised, double blind, national multicentre study.&#xD;
&#xD;
      Patients will be randomised into double-blind groups to receive (syringes will be identical&#xD;
      in appearance) in consecutively numbered boxes:&#xD;
&#xD;
      A - Parnaparin, dose of 8,500 IU aXa taken subcutaneously once a day for 10 days B -&#xD;
      Parnaparin, dose of 8,500 IU aXa per day for 10 days followed by Parnaparin 6,400 IU aXa per&#xD;
      day for the subsequent three weeks. C - Parnaparin, dose of 4,250 IU aXa per day for 30 days&#xD;
      Elastic compression treatment will be recommended with special stocking and/or elastic&#xD;
      bandaging with compression to the ankles of 20-40 mmHg, where not contraindicated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary effectiveness objectives</measure>
    <time_frame>33 days</time_frame>
    <description>composite of symptomatic and asymptomatic DVT, relapse and/or symptomatic or asymptomatic local extension of SVT and symptomatic PE at 33 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>33</time_frame>
    <description>Bleeding events were defined as major if retroperitoneal, intracranial, intraocular with severe vision damage, intra-articular, intra-abdominal of upper or lower digestive tract, genito-urinary tract, respiratory tract or associated with a decrease in the haemoglobin of ≥ 2.0 g/dL, or if requiring transfusion of ≥2 units of blood or if fatal.&#xD;
Bleeding was classified as minor in all other cases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary effectiveness objectives</measure>
    <time_frame>93</time_frame>
    <description>i)- reduction in local symptoms during treatment and ii)- the combined efficacy end-point during a follow-up of 93 days after the start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>secondary outcome for safety</measure>
    <time_frame>33</time_frame>
    <description>the composite of minor haemorrhages, thrombocytopenia or any other adverse events (e.g. local allergic reactions).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">664</enrollment>
  <condition>Thrombophlebitis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A - Parnaparin 8.500 UI aXa od (therapeutic doses) for 10 days followed by placebo for 20 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>B - Parnaparin 8.500 UI aXa od for 10 days followed by 6.400 UI aXa once daily (intermediate therapeutic doses) for 20 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>C - Parnaparin 4.250 UI aXa od (prophylactic doses) for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LMWH parnaparin subcutaneously</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Weight &gt; 50 kg and less than 110 kg&#xD;
&#xD;
          -  SVT of the grand saphenous vein for at least 4 cm&#xD;
&#xD;
          -  SVT of the small saphenous vein for at least 4 cm&#xD;
&#xD;
          -  Collateral SVT of the large saphenous vein of the thigh for at least 4cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  SVT of the grand saphenous vein reaching the saphenofemoral cross (within 3 cm)&#xD;
&#xD;
          -  SVT of the small saphenous vein reaching the saphenopopliteal cross&#xD;
&#xD;
          -  Documented proximal or distal DVT or pulmonary embolism&#xD;
&#xD;
          -  SVT secondary to sclerotherapy&#xD;
&#xD;
          -  Pregnancy and puerperium&#xD;
&#xD;
          -  uncontrolled arterial hypertension (Systolic pressure &gt; 180 mmHg and diastolic&#xD;
             pressure &gt; 110 mmHg)&#xD;
&#xD;
          -  Active peptic ulcer&#xD;
&#xD;
          -  Bacterial endocarditis&#xD;
&#xD;
          -  Stroke in the previous 3 months&#xD;
&#xD;
          -  Haemorrhagic diathesis&#xD;
&#xD;
          -  Thrombocytopenia (platelets &lt; 100,000/ µL)&#xD;
&#xD;
          -  Hypersensitivity to heparin or history of thrombocytopenia induced by heparin&#xD;
&#xD;
          -  Creatinine &gt; 2 mg% (&gt; 180 µmol/L)&#xD;
&#xD;
          -  Heparin therapy (any dose) or anticoagulant therapy for longer than the previous 72&#xD;
             hours&#xD;
&#xD;
          -  In-hospital development of SVT&#xD;
&#xD;
          -  Previous saphenectomy by any method&#xD;
&#xD;
          -  Surgery in the previous 30 days&#xD;
&#xD;
          -  Serious liver disease&#xD;
&#xD;
          -  Use of dextran, mannitol, thrombolytic treatment, chronic use of NSAID and&#xD;
             cortisone-based drugs.&#xD;
&#xD;
          -  Active cancer or under chemotherapy or radiotherapy&#xD;
&#xD;
          -  Thrombectomy of superficial vein involved&#xD;
&#xD;
          -  Refusal to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gualtiero Palareti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Bologna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benilde Cosmi, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bologna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. Angiology &amp; Blood Coagulation; University Hospital S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Medicina Critica</name>
      <address>
        <city>Piacenza</city>
        <state>PC</state>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 11, 2006</study_first_submitted>
  <study_first_submitted_qc>August 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>GUALTIERO PALARETI</investigator_full_name>
    <investigator_title>Prof.Gualtiero Palareti</investigator_title>
  </responsible_party>
  <keyword>Superficial vein thrombosis</keyword>
  <keyword>thrombophlebitis</keyword>
  <keyword>LMWH</keyword>
  <keyword>parnaparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Thrombophlebitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parnaparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

